A novel immunotherapy using HER2-specific CAR T cells showed promising results in a phase 1 trial for advanced sarcomas, with half of patients achieving either a complete response or stable disease. The trial’s next phase will investigate adding an immune checkpoint inhibitor. Despite challenges in treating sarcomas, targeted therapy like HER2 has shown potential benefits. The study had a positive safety profile, with two patients experiencing dose-limiting side effects. Researchers are hopeful about the future of CAR T therapy in combination with other treatments, aiming for better outcomes for patients with solid tumors in the future.
Source link
Benefits of novel CAR T-cell therapy ‘a big deal’ for patients with sarcoma
